Pharmacological antiemetic prophylaxis and treatment for opioid-induced nausea and vomiting (OINV) in patients treated for cancer pain and cancer-related breathlessness
- PMID: 40878845
- PMCID: PMC12395543
- DOI: 10.1002/14651858.CD016207
Pharmacological antiemetic prophylaxis and treatment for opioid-induced nausea and vomiting (OINV) in patients treated for cancer pain and cancer-related breathlessness
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of pharmacological treatments given prophylactically or on-demand after onset of opioid-induced nausea and vomiting (OINV) in people being treated for cancer pain or cancer dyspnoea, when compared to placebo or other pharmacological interventions.
Copyright © 2025 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Conflict of interest statement
JG: no commercial or non‐commercial conflicts of interest relevant to this review. He is a specialist palliative care physician and manages palliative care patients.
CAH: no commercial or non‐commercial conflicts of interest relevant to this review. He works as a medical information specialist.
VP: no commercial or non‐commercial conflicts of interest relevant to this review.
GS: received personal consulting fees for 'External statistical consultant of Roche Pharma AG, Grenzach‐Wyhlen, Germany'
CR: no commercial or non‐commercial conflicts of interest relevant to this review. She is a pharmacist leading the Competence Centre for Palliative Pharmacy.
KS: no commercial or non‐commercial conflicts of interest relevant to this review. She is a pharmacist and project manager.
CB: planned an investigator‐initiated study that is potentially eligible for inclusion [52]. Therefore, he will not make study eligibility decisions about this study; if it is included, he will not extract data from it, carry out the risk of bias assessment, or perform GRADE assessments for comparisons and outcomes that include this study (section 5.6 of Cochrane’s Conflict of Interest Policy). CB is a specialist palliative care physician and manages palliative care patients.
Similar articles
-
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.Cochrane Database Syst Rev. 2016 Feb 2;2(2):CD007786. doi: 10.1002/14651858.CD007786.pub3. Cochrane Database Syst Rev. 2016. PMID: 26836199 Free PMC article.
-
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555. doi: 10.1002/14651858.CD012555.pub2. Cochrane Database Syst Rev. 2018. PMID: 30246876 Free PMC article.
-
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2. Cochrane Database Syst Rev. 2021. PMID: 34784425 Free PMC article.
-
Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007786. doi: 10.1002/14651858.CD007786.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2016 Feb 02;2:CD007786. doi: 10.1002/14651858.CD007786.pub3. PMID: 20824866 Updated.
-
Prophylactic antiemetics for adults receiving intravenous opioids in the acute care setting.Cochrane Database Syst Rev. 2022 May 19;5(5):CD013860. doi: 10.1002/14651858.CD013860.pub2. Cochrane Database Syst Rev. 2022. PMID: 35588093 Free PMC article.
References
-
- Henson LA, Maddocks M, Evans C, Davidson M, Hicks S, Higginson IJ. Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue. Journal of Clinical Oncology 2020;38(9):905-14. [DOI: 10.1200/JCO.19.00470] - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical